Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.